Iron overload treatment leads Shire to acquire FerroKin

03/15/2012 | Fox Business · Xconomy

FerroKin's lead drug candidate, FBS0701, is in midstage clinical trials to treat iron overload in people who have received multiple blood transfusions. Shire said it will buy the biotech firm as part of an effort to expand its hematology business. Shire agreed to pay $100 million in cash, plus as much as $225 million in milestone payments.

View Full Article in:

Fox Business · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN